Glossary entry (derived from question below)
English term or phrase:
me-too drugs
Greek translation:
φάρμακα ίδιου σκοπού
Added to glossary by
daira
Apr 11, 2023 07:02
1 yr ago
24 viewers *
English term
me-too drugs
English to Greek
Social Sciences
Medical: Health Care
patents
he existing patent regime also hugely overrewards me-too drugs, which supply a new molecule to tackle a problem for which other molecules are already available.
Proposed translations
(Greek)
| 3 +4 | φάρμακα ίδιου σκοπού |
D. Harvatis
|
| 3 | παράγωγα φάρμακα |
Haralabos Papatheodorou
|
| 3 | Βιο-ομοειδή φάρμακα |
Anastasia Kalantzi
|
Proposed translations
+4
1 hr
D. Harvatis
Native in Greek
Specializes in field
Biomedical translations
Native in: Greek 
Works in: English to Greek, French to Greek, German to Greek, and 1 more.
Related KudoZ points
:
86
Selected
φάρμακα ίδιου σκοπού
Έτσι τα αποκαλεί το Ευρωπαϊκό Κοινοβούλιο, και νομίζω ότι είναι καλή απόδοση.
4 KudoZ points awarded for this answer.
5 mins
Haralabos Papatheodorou
Greece
Greece
Native in Greek
Specializes in field
Greece
Medical Translations | MD, MSc, PhD
Native in: Greek (Variant: Modern)
Works in: English to Greek, Greek
Related KudoZ points
:
40
παράγωγα φάρμακα
παράγωγα φάρμακα, φάρμακα μοριακά τροποποιημένα, φάρμακα follow-up
Ο όρος «me-too φάρμακο» χρησιμοποιείται για να περιγρά-
ψει ένα φαρμακευτικό προϊόν, το οποίο είναι συνήθως δο-
μικά παρόμοιο με ένα φάρμακο που ήδη κυκλοφορεί στην
αγορά. Άλλες ονομασίες που χρησιμοποιούνται είναι πα-
ράγωγα φάρμακα, φάρμακα μοριακά τροποποιημένα και
φάρμακα follow-up. Σε ορισμένες περιπτώσεις, ένα ουσιω-
δώς όμοιο ή me-too φάρμακο είναι ένα διαφορετικό μόριο
που αναπτύχθηκε σκόπιμα από μία ανταγωνιστική εταιρεία,
για να διεκδικήσει ένα μερίδιο της αγοράς από την εται-
ρεία, η οποία διαθέτει ήδη δικά της φάρμακα στην αγορά
--------------------------------------------------
Note added at 11 mins (2023-04-11 07:14:16 GMT)
--------------------------------------------------
Κλινικά ισοδύναμο φάρμακο (https://www.translatum.gr/forum/index.php?topic=512529.0)
--------------------------------------------------
Note added at 13 mins (2023-04-11 07:16:09 GMT)
--------------------------------------------------
" τονίζει ότι, ενώ ορισμένα νέα φάρμακα αποτελούν παραδείγματα επαναστατικής καινοτομίας, άλλα νέα φάρμακα επιδεικνύουν θεραπευτική προστιθέμενη αξία ανεπαρκή για να χαρακτηριστούν γνήσια καινοτομία (ουσίες ίδιου σκοπού –«me-too»)·" (https://www.europarl.europa.eu/doceo/document/TA-8-2017-03-0...
--------------------------------------------------
Note added at 15 mins (2023-04-11 07:17:53 GMT)
--------------------------------------------------
Τα νέα φάρμακα που είναι δυνατόν να αναπτυχθούν με τέτοιου είδους έρευνα αποκαλούνται και “me too drugs”-(«υπάρχω και εγώ»). (https://users.auth.gr/vdem/BasikesArxesSxediasmou&Anapty3hsF...
Ο όρος «me-too φάρμακο» χρησιμοποιείται για να περιγρά-
ψει ένα φαρμακευτικό προϊόν, το οποίο είναι συνήθως δο-
μικά παρόμοιο με ένα φάρμακο που ήδη κυκλοφορεί στην
αγορά. Άλλες ονομασίες που χρησιμοποιούνται είναι πα-
ράγωγα φάρμακα, φάρμακα μοριακά τροποποιημένα και
φάρμακα follow-up. Σε ορισμένες περιπτώσεις, ένα ουσιω-
δώς όμοιο ή me-too φάρμακο είναι ένα διαφορετικό μόριο
που αναπτύχθηκε σκόπιμα από μία ανταγωνιστική εταιρεία,
για να διεκδικήσει ένα μερίδιο της αγοράς από την εται-
ρεία, η οποία διαθέτει ήδη δικά της φάρμακα στην αγορά
--------------------------------------------------
Note added at 11 mins (2023-04-11 07:14:16 GMT)
--------------------------------------------------
Κλινικά ισοδύναμο φάρμακο (https://www.translatum.gr/forum/index.php?topic=512529.0)
--------------------------------------------------
Note added at 13 mins (2023-04-11 07:16:09 GMT)
--------------------------------------------------
" τονίζει ότι, ενώ ορισμένα νέα φάρμακα αποτελούν παραδείγματα επαναστατικής καινοτομίας, άλλα νέα φάρμακα επιδεικνύουν θεραπευτική προστιθέμενη αξία ανεπαρκή για να χαρακτηριστούν γνήσια καινοτομία (ουσίες ίδιου σκοπού –«me-too»)·" (https://www.europarl.europa.eu/doceo/document/TA-8-2017-03-0...
--------------------------------------------------
Note added at 15 mins (2023-04-11 07:17:53 GMT)
--------------------------------------------------
Τα νέα φάρμακα που είναι δυνατόν να αναπτυχθούν με τέτοιου είδους έρευνα αποκαλούνται και “me too drugs”-(«υπάρχω και εγώ»). (https://users.auth.gr/vdem/BasikesArxesSxediasmou&Anapty3hsF...
2 hrs
Anastasia Kalantzi
Greece
Greece
Native in Greek
Greece
EnFrGreek Medical/Mechanical/Legal
Native in: Greek (Variant: Modern) , Greek (Ancient) (Variants: Koine (common), Doric, Homeric, Ionic, Aeolic) 
Works in: French to Greek, Greek to French, English to Greek, and 5 more.
Βιο-ομοειδή φάρμακα
Βιο-ομοειδή φάρμακα, σύμφωνα με τον Ευρωπαϊκό Οργανισμό Φαρμάκων (EMA)
https://www.newsbomb.gr/ygeia/farmako/story/1053579/ti-einai...
Βιο-ομοειδές είναι ένα φάρμακο εξαιρετικά παρόμοιο με ένα άλλο βιολογικό φάρμακο που ήδη έχει πάρει άδεια κυκλοφορίας στην ΕΕ (το αποκαλούμενο φάρμακο αναφοράς) και του οποίου έχει λήξει η πατέντα. Ως βιολογικά φάρμακα, τα βιο-ομοειδή παράγονται με τη χρήση προηγμένης βιοτεχνολογίας σε συστήματα ζώντων κυττάρων ακολουθώντας τις ίδιες διαδικασίες και απαιτήσεις ελέγχου όπως και τα φάρμακα αναφοράς τους, σύμφωνα με τον Ευρωπαϊκό Οργανισμό Φαρμάκων (EMA).
https://www.ema.europa.eu/en/documents/leaflet/biosimilars-e...
--------------------------------------------------
Note added at 1 ώρα (2023-04-11 08:43:33 GMT)
--------------------------------------------------
https://ellok.org/βιο-ομοειδη/
https://magdasnews.gr/tag/viomoeidi-farmaka/
--------------------------------------------------
Note added at 2 ώρες (2023-04-11 09:09:29 GMT)
--------------------------------------------------
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576625/
Me‐too pharmaceutical products: History, definitions, examples, and relevance to drug shortages and essential medicines lists
Jeffrey K. Aronsoncorresponding author 1 and A. Richard Green 2
Author information Article notes Copyright and License information Disclaimer
Go to:
Abstract
We define a me‐too drug as a pharmacologically active compound that is structurally related to a first‐in‐class compound, regarded as belonging to the same therapeutic class as the original compound, and used for the same therapeutic purposes, but which may differ in some respects, such as specificity of pharmacological action, adverse reactions profile, or drug–drug interactions. We also offer definitions of related terms, including follow‐on drug and first‐in‐class. The therapeutic advantages of me‐too drugs may include improved target specificity, reduced risks of off‐target adverse reactions and drug–drug interactions, increased chance of benefit in some patients, and improved drug delivery and pharmacokinetics. Me‐too drugs can also demonstrate incremental innovation. Their availability may help in coping with drug shortages. However, they may occasionally cause unexpected adverse reactions that are not class effects. Tricyclic antidepressants, β‐blockers, and statins illustrate the diversity of me‐too drugs. Earlier compounds may be as effective as later ones, or more so. Tricyclic antidepressants have similar chemical structures, and compounds introduced after the first‐in‐class compound (imipramine) mostly offered little in the way of innovative features, but continue to be prescribed. In contrast, me‐too β‐blockers introduced after the first‐in‐class compound, pronethalol, have diverse structures and display several innovative features. Stereoisomers and biosimilars/biobetters provide special examples of me‐too drugs. Although many me‐too drugs offer no significant advantages over their predecessors, over 60% of the drugs listed on the World Health Organization's essential list are me‐toos. Different countries may choose different me‐too drugs when constructing essential medicines lists, partly explaining transnational differences between them.
--------------------------------------------------
Note added at 2 ώρες (2023-04-11 09:16:09 GMT)
--------------------------------------------------
***https://en.wikipedia.org/wiki/Me-too_drug
The term "me-too drug" or "follow-on drug" refers to a medication that is similar to a pre-existing drug, usually by making minor modifications to the prototype, reflected in slight changes in the profiles of side effects or activity, and used to treat conditions for which drugs already exist.[1][2] While pharmaceutical companies have justified the development of me-toos as offering incremental improvements in efficacy, side-effects, compliance and cost, critics have questioned the increasing marketing of me-toos, their absorption of research and development resources and their impact on the innovation of new treatments.[3][4][5]
In 1956, Louis S. Goodman, co‐editor of Goodman and Gilman, referred to “the problem of the introduction of ‘me too’ drugs, that is, drugs without signal advantage of any sort”.[1] However, me-too drugs can be novel compounds themselves.[3][6] They are commonly used and include several beta blockers, antidepressants and stomach acid reducing and cholesterol lowering drugs.[1]
--------------------------------------------------
Note added at 2 ώρες (2023-04-11 09:36:08 GMT)
--------------------------------------------------
***tereoisomers and biosimilars/biobetters provide special examples of me‐too drugs. Although many me‐too drugs offer no significant advantages over their predecessors, over 60% of the drugs listed on the World Health Organization's essential list are me‐toos.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576625/
AND
https://bpspubs.onlinelibrary.wiley.com/doi/abs/10.1111/bcp....
από JK Aronson · 2020 · Γίνεται αναφορά σε 41 — Stereoisomers and biosimilars/biobetters provide special examples of me-too drugs. Although many me-too drugs offer no significant .
--------------------------------------------------
Note added at 2 ώρες (2023-04-11 09:37:11 GMT)
--------------------------------------------------
****Stereoisomers, in the last reference, and not ''tereoisomers''.
--------------------------------------------------
Note added at 4 ώρες (2023-04-11 11:29:06 GMT)
--------------------------------------------------
*** EDITED RESPONSE : ΒΙΟ-ΟΜΟΕΙΔΗ Ή ΓΕΝΟΣΗΜΑ ΦΑΡΜΑΚΑ.
https://www.newsbomb.gr/ygeia/farmako/story/1053579/ti-einai...
Βιο-ομοειδές είναι ένα φάρμακο εξαιρετικά παρόμοιο με ένα άλλο βιολογικό φάρμακο που ήδη έχει πάρει άδεια κυκλοφορίας στην ΕΕ (το αποκαλούμενο φάρμακο αναφοράς) και του οποίου έχει λήξει η πατέντα. Ως βιολογικά φάρμακα, τα βιο-ομοειδή παράγονται με τη χρήση προηγμένης βιοτεχνολογίας σε συστήματα ζώντων κυττάρων ακολουθώντας τις ίδιες διαδικασίες και απαιτήσεις ελέγχου όπως και τα φάρμακα αναφοράς τους, σύμφωνα με τον Ευρωπαϊκό Οργανισμό Φαρμάκων (EMA).
https://www.ema.europa.eu/en/documents/leaflet/biosimilars-e...
--------------------------------------------------
Note added at 1 ώρα (2023-04-11 08:43:33 GMT)
--------------------------------------------------
https://ellok.org/βιο-ομοειδη/
https://magdasnews.gr/tag/viomoeidi-farmaka/
--------------------------------------------------
Note added at 2 ώρες (2023-04-11 09:09:29 GMT)
--------------------------------------------------
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576625/
Me‐too pharmaceutical products: History, definitions, examples, and relevance to drug shortages and essential medicines lists
Jeffrey K. Aronsoncorresponding author 1 and A. Richard Green 2
Author information Article notes Copyright and License information Disclaimer
Go to:
Abstract
We define a me‐too drug as a pharmacologically active compound that is structurally related to a first‐in‐class compound, regarded as belonging to the same therapeutic class as the original compound, and used for the same therapeutic purposes, but which may differ in some respects, such as specificity of pharmacological action, adverse reactions profile, or drug–drug interactions. We also offer definitions of related terms, including follow‐on drug and first‐in‐class. The therapeutic advantages of me‐too drugs may include improved target specificity, reduced risks of off‐target adverse reactions and drug–drug interactions, increased chance of benefit in some patients, and improved drug delivery and pharmacokinetics. Me‐too drugs can also demonstrate incremental innovation. Their availability may help in coping with drug shortages. However, they may occasionally cause unexpected adverse reactions that are not class effects. Tricyclic antidepressants, β‐blockers, and statins illustrate the diversity of me‐too drugs. Earlier compounds may be as effective as later ones, or more so. Tricyclic antidepressants have similar chemical structures, and compounds introduced after the first‐in‐class compound (imipramine) mostly offered little in the way of innovative features, but continue to be prescribed. In contrast, me‐too β‐blockers introduced after the first‐in‐class compound, pronethalol, have diverse structures and display several innovative features. Stereoisomers and biosimilars/biobetters provide special examples of me‐too drugs. Although many me‐too drugs offer no significant advantages over their predecessors, over 60% of the drugs listed on the World Health Organization's essential list are me‐toos. Different countries may choose different me‐too drugs when constructing essential medicines lists, partly explaining transnational differences between them.
--------------------------------------------------
Note added at 2 ώρες (2023-04-11 09:16:09 GMT)
--------------------------------------------------
***https://en.wikipedia.org/wiki/Me-too_drug
The term "me-too drug" or "follow-on drug" refers to a medication that is similar to a pre-existing drug, usually by making minor modifications to the prototype, reflected in slight changes in the profiles of side effects or activity, and used to treat conditions for which drugs already exist.[1][2] While pharmaceutical companies have justified the development of me-toos as offering incremental improvements in efficacy, side-effects, compliance and cost, critics have questioned the increasing marketing of me-toos, their absorption of research and development resources and their impact on the innovation of new treatments.[3][4][5]
In 1956, Louis S. Goodman, co‐editor of Goodman and Gilman, referred to “the problem of the introduction of ‘me too’ drugs, that is, drugs without signal advantage of any sort”.[1] However, me-too drugs can be novel compounds themselves.[3][6] They are commonly used and include several beta blockers, antidepressants and stomach acid reducing and cholesterol lowering drugs.[1]
--------------------------------------------------
Note added at 2 ώρες (2023-04-11 09:36:08 GMT)
--------------------------------------------------
***tereoisomers and biosimilars/biobetters provide special examples of me‐too drugs. Although many me‐too drugs offer no significant advantages over their predecessors, over 60% of the drugs listed on the World Health Organization's essential list are me‐toos.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576625/
AND
https://bpspubs.onlinelibrary.wiley.com/doi/abs/10.1111/bcp....
από JK Aronson · 2020 · Γίνεται αναφορά σε 41 — Stereoisomers and biosimilars/biobetters provide special examples of me-too drugs. Although many me-too drugs offer no significant .
--------------------------------------------------
Note added at 2 ώρες (2023-04-11 09:37:11 GMT)
--------------------------------------------------
****Stereoisomers, in the last reference, and not ''tereoisomers''.
--------------------------------------------------
Note added at 4 ώρες (2023-04-11 11:29:06 GMT)
--------------------------------------------------
*** EDITED RESPONSE : ΒΙΟ-ΟΜΟΕΙΔΗ Ή ΓΕΝΟΣΗΜΑ ΦΑΡΜΑΚΑ.
Peer comment(s):
| neutral |
D. Harvatis
: Ο όρος «βιοομοειδή» αποδίδει το biosimilar, που δεν ταυτίζεται με το me-too (όπως φαίνεται κι από την τελευταία πηγή). // Το "provide special examples" σημαίνει ότι ο όρος me-too είναι ευρύτερος, ενώ τα biosimilars είναι υποκατηγορία του.
1 hr
|
|
Μα εφόσον πιο πάνω αναφέρει ότι provide special examples of me-too drugs! Είναι τα δικά μας, γνωστά ως γενόσημα./Εμείς πάλι το λέμε ''όχι Γιάννη, Γιαννάκη!''..Καλή Ανάσταση!
|
Something went wrong...